Assembly Biosciences (ASMB) Competitors $11.39 -0.12 (-1.04%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ASMB vs. NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Assembly Biosciences vs. Nektar Therapeutics Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Nektar Therapeutics (NASDAQ:NKTR) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings. Is NKTR or ASMB more profitable? Assembly Biosciences has a net margin of -144.05% compared to Nektar Therapeutics' net margin of -180.70%. Assembly Biosciences' return on equity of -121.46% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-180.70% -173.28% -46.31% Assembly Biosciences -144.05%-121.46%-34.56% Which has more risk and volatility, NKTR or ASMB? Nektar Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Do insiders & institutionals have more ownership in NKTR or ASMB? 75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 3.7% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to NKTR or ASMB? In the previous week, Nektar Therapeutics had 4 more articles in the media than Assembly Biosciences. MarketBeat recorded 6 mentions for Nektar Therapeutics and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.34 beat Nektar Therapeutics' score of 1.25 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, NKTR or ASMB? Assembly Biosciences has lower revenue, but higher earnings than Nektar Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$98.43M1.50-$276.06M-$0.59-1.35Assembly Biosciences$28.52M3.05-$61.23M-$6.72-1.69 Do analysts rate NKTR or ASMB? Nektar Therapeutics currently has a consensus price target of $4.50, suggesting a potential upside of 465.68%. Assembly Biosciences has a consensus price target of $33.00, suggesting a potential upside of 189.73%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community believe in NKTR or ASMB? Nektar Therapeutics received 394 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.73% of users gave Nektar Therapeutics an outperform vote while only 58.65% of users gave Assembly Biosciences an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes63870.73% Underperform Votes26429.27% Assembly BiosciencesOutperform Votes24458.65% Underperform Votes17241.35% SummaryNektar Therapeutics beats Assembly Biosciences on 12 of the 19 factors compared between the two stocks. Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.00M$6.89B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-1.697.4422.4418.48Price / Sales3.05242.66394.66103.91Price / CashN/A65.8538.1834.62Price / Book1.526.516.774.25Net Income-$61.23M$143.21M$3.22B$248.23M7 Day Performance9.41%3.97%3.09%3.29%1 Month Performance7.25%0.37%-0.14%2.43%1 Year Performance-8.66%2.59%17.98%5.54% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences3.8105 of 5 stars$11.39-1.0%$33.00+189.7%-8.7%$87.00M$28.52M-1.69100Upcoming EarningsNews CoveragePositive NewsNKTRNektar Therapeutics4.0798 of 5 stars$0.63-1.6%$4.50+619.0%-45.5%$116.48M$98.43M-0.75220Upcoming EarningsPositive NewsCPIXCumberland Pharmaceuticals0.8711 of 5 stars$4.49-5.7%N/A+201.9%$62.72M$37.87M-5.8380Upcoming EarningsShort Interest ↓News CoveragePositive NewsLLYEli Lilly and Company4.9186 of 5 stars$818.18-2.6%$1,012.00+23.7%+15.1%$775.77B$45.04B69.8739,000Analyst DowngradeJNJJohnson & Johnson4.3024 of 5 stars$157.00-0.3%$171.82+9.4%+8.1%$378.35B$88.82B23.61152,700ABBVAbbVie4.6172 of 5 stars$170.01-1.7%$210.71+23.9%+20.0%$300.74B$56.33B70.8450,000Earnings ReportAnalyst ForecastAnalyst RevisionMRKMerck & Co., Inc.5 of 5 stars$77.91-0.1%$115.50+48.2%-34.0%$196.47B$64.17B11.5869,000Earnings ReportInsider TradePFEPfizer4.9766 of 5 stars$22.07-0.3%$31.07+40.8%-4.7%$125.17B$63.63B15.6583,000Earnings ReportDividend AnnouncementAnalyst ForecastNews CoverageBMYBristol-Myers Squibb4.6257 of 5 stars$48.95-0.6%$57.67+17.8%+14.2%$99.60B$48.30B-11.0734,300Earnings ReportInsider TradeAnalyst RevisionZTSZoetis4.5125 of 5 stars$146.85-1.2%$214.40+46.0%-1.6%$65.52B$9.26B26.8513,800Upcoming EarningsOptions VolumePositive NewsRPRXRoyalty Pharma4.3455 of 5 stars$32.19-1.3%$42.50+32.0%+18.5%$18.56B$2.26B22.2080Upcoming EarningsPositive News Related Companies and Tools Related Companies Nektar Therapeutics Alternatives Cumberland Pharmaceuticals Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASMB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASMB Stock Free ASMB Stock Alerts